Neurocrine Biosciences, Inc. $NBIX Shares Sold by Burney Co.

Burney Co. lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 38.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,321 shares of the company’s stock after selling 3,369 shares during the period. Burney Co.’s holdings in Neurocrine Biosciences were worth $701,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NBIX. Royal Bank of Canada grew its holdings in shares of Neurocrine Biosciences by 36.7% during the first quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock valued at $9,158,000 after purchasing an additional 22,224 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Neurocrine Biosciences by 60.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock worth $1,647,000 after purchasing an additional 5,577 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Neurocrine Biosciences by 56.3% in the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock worth $844,000 after purchasing an additional 2,747 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth approximately $1,333,000. Finally, Geneos Wealth Management Inc. boosted its position in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings upgraded Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 24th. Guggenheim reiterated a “buy” rating and issued a $175.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. HC Wainwright upped their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Wedbush increased their price objective on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $188.10.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $180.55 on Friday. The stock has a market cap of $18.15 billion, a price-to-earnings ratio of 27.82, a PEG ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $181.00. The business has a fifty day moving average of $159.92 and a 200-day moving average of $142.66.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 8,433 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $178.72, for a total transaction of $1,507,145.76. Following the sale, the insider directly owned 16,225 shares in the company, valued at approximately $2,899,732. The trade was a 34.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares of the company’s stock, valued at approximately $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 379,805 shares of company stock valued at $59,634,666. Corporate insiders own 4.60% of the company’s stock.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX was upgraded to Zacks Rank #1 (Strong Buy), signaling improved earnings optimism and potentially supporting further upside. Article Title
• Positive Sentiment: News that Neurocrine has started a Phase 2 CAH study in children under 4 may be encouraging for the pipeline, and another article suggested the stock could be undervalued after the new study. Article Title Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30; this is important upcoming catalyst news, but it does not change fundamentals by itself. Article Title
• Neutral Sentiment: A separate note said NBIX looks fair on earnings but pricey versus biotechs, which is more of a valuation check than a clear stock-moving event. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in three transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which limits how bearish the signal is, but insider selling can still temper enthusiasm. Article Title

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.